Antidepressant Drugs Market By Type (Serotonin and Noradrenaline Reuptake Inhibitors (SNRIs), Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressants (TCAs), Monoamine Oxidase Inhibitors (MAOIs), Noradrenaline and Specific Serotoninergic Antidepressants (NASSAs); By Mode of Administration (Tablets and Capsules, Liquids, Injections, Inhalation, Others) ; By End-Users (Hospitals and Clinics, Pharmacies, Urgent Care Centers, Research Institutes, Others); By Disorder Type (Major and Minor Depression, Obsessive Compulsive Disorder, Generalized Anxiety , Posttraumatic Stress (PTSD), Social Anxiety , Agitation and Stress , Bipolar Disorder, Others); By Region (U.S., Canada, Mexico, Rest of North America, The UK, France, Germany, Italy, Spain, Nordic Countries (Denmark, Finland, Iceland, Sweden, Norway), Benelux Union (Belgium, the Netherlands, Luxembourg), Rest of Europe, China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia), Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa, Brazil, Argentina, Rest of Latin America) – Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2020 – 2028
- Industry Trends
The life of human beings have become highly complex in recent times, and remarks such as life was less complicated years back are often heard. Change in lifestyle, especially in cities and towns, is being seen around the globe. Urbanization efforts by government bodies and higher income offered in urban locations can be cited as a major reason for the migration of people towards cities and towns. Job-related stress, especially in developing and developed countries, is a leading cause of depression. Furthermore, there is an increased chance of depression in individuals who have got a family history of depression, experienced childhood trauma, a less active frontal lobe in the brain and consumption of drugs, amongst others. In case of drug use, studies show that around 21% of individuals who have used banned substances (drugs) experience depression at some stage in their life, which in turn is increasing the demand of antidepressant drugs market. Common symptoms of depression include mood swings, loss in appetite, irregular sleep patterns, suicidal thoughts, fatigue, etc. Based on the World Health Organization (WHO) statistics, depression affects more than 264 million human beings globally. It is also the leading cause of disability and contributes significantly towards the global disease burden. Government bodies in countries like India, China, US, the UK, France, etc., and world organizations, are increasingly focussing on providing effective treatments to combat the rise in cases of depression. The WHO, for example, has formulated a mental health awareness program called as mental health Gap Action Programme (mhGAP) which aims at providing medical care to those individuals who are affected by depression. Several treatment methods have been proven effective in the treatment of depression. Medical practitioners recommend psychological methods like behavioural therapy, interpersonal psychotherapy, and cognitive behavioural therapy (CBT). In other cases, antidepressant drugs are provided to the patients, mainly through prescriptions. Selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs) are commonly prescribed by healthcare professionals. These drugs are effective in cases of moderate to severe depression. In the UK, for instance, around 10.4% individuals who seek medical treatment for depression are prescribed antidepressant drugs. Furthermore, there has been a considerable increase in the number of individuals seeking medical help for depression, as the stigma associated with the disease is decreasing globally. The rise in awareness amongst individuals regarding depression, coupled with the effectiveness of antidepressants in the treatment of the mental disease is leading to the growth of the global antidepressant drugs market.
Concerns regarding the side effects associated with antidepressants, coupled with the regulatory compliance for the manufacture of antidepressant drug is hindering the growth of the global antidepressant drugs market. In the case of selective serotonin reuptake inhibitors (SSRIs) and serotonin-noradrenaline reuptake inhibitors (SNRIs), for instance, the United Kingdom National Health Service states that side effects like increased anxiety, agitation, indigestion, dizziness, low sex drive, etc., can be seen during the initial months of antidepressant intake. Moreover, a health condition called serotonin syndrome is a potentially serious side effect associated with SSRI and SNRIs. These occur when individuals consume antidepressants along with drugs or substances that raise the serotonin levels in the brain. Periodic consultation with healthcare professionals regarding the effectiveness of the medication is of utmost importance in the case of antidepressants, since drug overdose and addiction can also be seen in certain cases. Furthermore, antidepressant drugs are not recommended for mild cases of depression, mainly because of these side effects. Higher awareness regarding the use of antidepressants, and efforts to reduce side effects in individuals will help in the growth of the global antidepressant drugs market in the coming years.
The COVID-19 pandemic has impacted the lives of numerous individuals across regions. Lockdown measures imposed in countries like Italy, France, India, etc., forced the individuals to stay indoors to curb the spread of the virus. Moreover, the economy has taken a severe hit, and jobs have been lost due to the pandemic. In India, for instance, studies show that around 4.1 million young adults have been laid off from work as a result of COVID-19. Concerns regarding job safety and lack of socialization amongst individuals is raising the number of individuals who are affected by depression. Studies show that in the U.S., for instance, there was a three-fold increase in depression symptoms in adults during the pandemic. Furthermore, the use of antidepressants for the treatment of COVID-19 patients is also being studied by researchers in Europe. Fluoxetine, a standard antidepressant drug, was found to reduce the replication of SARS-CoV-2 virus by the virologists and chemists at the University of Würzburg, Germany. These factors suggest that the COVID-19 pandemic is expected to have a positive impact on the global antidepressant drugs market.
In terms of revenue, global antidepressant drugs market was valued at US$ 24148.76 Mn in 2019 and is anticipated to grow at a CAGR of 12.13% over the forecast period (2020 – 2028). The study analyses the market in terms of revenue across all the major regions, which have been bifurcated into countries.
Global Antidepressant Drugs Market Revenue & Forecast, (US$ Million), 2015 – 2028
Type Outlook:
Selective Serotonin Reuptake Inhibitors (SSRIs) are the most commonly prescribed type of antidepressants. Serotonin and Noradrenaline Reuptake Inhibitors (SNRIs) and Tricyclic Antidepressants (TCAs) are also prescribed by health professionals, depending on the severity of depression. SNRIs are mainly used to treat severe cases of depression. They help in raising levels of serotonin and norepinephrine, which are neurotransmitters that determine mood stabilization in human beings. Some examples of SNRIs include venlafaxine (Effexor) and desvenlafaxine (Pristiq), duloxetine (Cymbalta), etc. As compared to SNRIs, SSRIs have fewer side effects, and are used to treat a broad range of illnesses. They are responsible for reducing the absorption of serotonin in the brain. They mainly affect on serotonin, leaving the other neurotransmitters unharmed. Some of the commonly prescribed SSRIs are scitalopram (Lexapro), fluoxetine (Prozac, Sarafem), ertraline (Zoloft), amongst others. Due to the fewer side effects and its ability to treat depression of varying magnitude, SSRIs accounted for a significant share in the global antidepressant drugs market in 2018.
Region Outlook:
Based on the regions, North America accounted for the highest share in the global antidepressant drugs market in 2018. Rising cases of depression, coupled with the presence of prominent antidepressant drug manufacturers like Novartis, Sanofi, Abbot, etc., can be cited as a major reason for this. Companies in North America are also innovating on treating depression based on various causes. Massachusetts-based Sage Therapeutics, for instance, is researching on a new drug that is postpartum depression. The drug, SAGE-547, is based on allopregnanolone, which is a neuroactive metabolite of progesterone that plays a crucial role in the reproductive system in females. Such factors are aiding for the growth of antidepressant drugs market.
Competitive Landscape
The report provides both, qualitative and quantitative research of antidepressant drugs market, as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analysed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.
Some of the players operating in the antidepressant drugs market are Abbot, AbbVie, AstraZeneca, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc., H. Lundbeck A/S, Janssen Pharmaceuticals, Inc., Lupin Pharmaceuticals, Inc., Merck & Co., Inc., Novartis AG, Pfizer Inc., sanofi-aventis U.S. LLC, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd, amongst others.
Global Antidepressant Drugs Market:
- By Type
- Serotonin and Noradrenaline Reuptake Inhibitors (Snris)
- Selective Serotonin Reuptake Inhibitors (Ssris)
- Tricyclic Antidepressants (Tcas)
- Monoamine Oxidase Inhibitors (Maois)
- Noradrenaline and Specific Serotoninergic Antidepressants (Nassas)
- By Mode of Administration
- Tablets and Capsules
- Liquids
- Injections
- Inhalation
- Others
- By End-Users
- Hospitals and Clinics
- Pharmacies
- Urgent Care Centers
- Research Institutes
- Others
- By Disorder Type
- Major and Minor Depression
- Obsessive Compulsive Disorder
- Generalized Anxiety
- Posttraumatic Stress (PTSD)
- Social Anxiety
- Agitation and Stress
- Bipolar Disorder
- Others
- By Region
- North America
- U.S
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
Table of Contents
1. Market
Scope
1.1. Market
Segmentation
1.2. Years
Considered
1.2.1. Historic
Years: 2013 - 2018
1.2.2. Base
Year: 2019
1.2.3. Forecast
Years: 2020 – 2028
2. Key Target
Audiences
3. Research
Methodology
3.1. Primary
Research
3.1.1. Research
Questionnaire
3.1.2. Global
Percentage Breakdown
3.1.3. Primary
Interviews: Key Opinion Leaders (KOLs)
3.2. Secondary
Research
3.2.1. Paid
Databases
3.2.2. Secondary
Sources
3.3. Market
Size Estimates
3.3.1. Top-Down
Approach
3.3.2. Bottom-Up
Approach
3.4. Data
Triangulation Methodology
3.5. Research
Assumptions
4. Recommendations
and Insights from AMI’s Perspective**
5. Holistic
Overview of Antidepressant Drugs Market
6. Market
Synopsis: Antidepressant Drugs Market
7. Antidepressant
Drugs Market Analysis: Qualitative Perspective
7.1. Introduction
7.1.1. Product
Definition
7.1.2. Industry
Development
7.2. Market
Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.3. Trends in
Antidepressant Drugs Market
7.4. Market
Determinants Radar Chart
7.5. Macro-Economic
and Micro-Economic Indicators: Antidepressant Drugs Market
7.6. Porter’s
Five Force Analysis
7.7. Impact of
Covid-19 on Antidepressant Drugs Market
8. Global
Antidepressant Drugs Market Analysis and Forecasts, 2020 – 2028
8.1. Overview
8.1.1. Global
Antidepressant Drugs Market Revenue (US$ Mn)
8.2. Global
Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Type
8.2.1. Serotonin
and Noradrenaline Reuptake Inhibitors (SNRIs)
8.2.1.1. Definition
8.2.1.2. Market
Estimation and Penetration, 2013 – 2019
8.2.1.3. Market
Forecast, 2020 – 2028
8.2.1.4. Compound
Annual Growth Rate (CAGR)
8.2.1.5. Regional
Bifurcation
8.2.1.5.1. North
America
8.2.1.5.1.1. Market
Estimation, 2013 – 2019
8.2.1.5.1.2. Market
Forecast, 2020 – 2028
8.2.1.5.2. Europe
8.2.1.5.2.1. Market
Estimation, 2013 – 2019
8.2.1.5.2.2. Market
Forecast, 2020 – 2028
8.2.1.5.3. Asia
Pacific
8.2.1.5.3.1. Market
Estimation, 2013 – 2019
8.2.1.5.3.2. Market
Forecast, 2020 – 2028
8.2.1.5.4. Middle
East and Africa
8.2.1.5.4.1. Market
Estimation, 2013 – 2019
8.2.1.5.4.2. Market
Forecast, 2020 – 2028
8.2.1.5.5. Latin
America
8.2.1.5.5.1. Market
Estimation, 2013 – 2019
8.2.1.5.5.2. Market
Forecast, 2020 – 2028
8.2.2. Selective
Serotonin Reuptake Inhibitors (SSRIs)
8.2.2.1. Definition
8.2.2.2. Market
Estimation and Penetration, 2013 – 2019
8.2.2.3. Market
Forecast, 2020 – 2028
8.2.2.4. Compound
Annual Growth Rate (CAGR)
8.2.2.5. Regional
Bifurcation
8.2.2.5.1. North
America
8.2.2.5.1.1. Market
Estimation, 2013 – 2019
8.2.2.5.1.2. Market
Forecast, 2020 – 2028
8.2.2.5.2. Europe
8.2.2.5.2.1. Market
Estimation, 2013 – 2019
8.2.2.5.2.2. Market
Forecast, 2020 – 2028
8.2.2.5.3. Asia
Pacific
8.2.2.5.3.1. Market
Estimation, 2013 – 2019
8.2.2.5.3.2. Market
Forecast, 2020 – 2028
8.2.2.5.4. Middle
East and Africa
8.2.2.5.4.1. Market
Estimation, 2013 – 2019
8.2.2.5.4.2. Market
Forecast, 2020 – 2028
8.2.2.5.5. Latin
America
8.2.2.5.5.1. Market
Estimation, 2013 – 2019
8.2.2.5.5.2. Market
Forecast, 2020 – 2028
8.2.3. Tricyclic
Antidepressants (TCAs)
8.2.3.1. Definition
8.2.3.2. Market
Estimation and Penetration, 2013 – 2019
8.2.3.3. Market
Forecast, 2020 – 2028
8.2.3.4. Compound
Annual Growth Rate (CAGR)
8.2.3.5. Regional
Bifurcation
8.2.3.5.1. North
America
8.2.3.5.1.1. Market
Estimation, 2013 – 2019
8.2.3.5.1.2. Market
Forecast, 2020 – 2028
8.2.3.5.2. Europe
8.2.3.5.2.1. Market
Estimation, 2013 – 2019
8.2.3.5.2.2. Market
Forecast, 2020 – 2028
8.2.3.5.3. Asia
Pacific
8.2.3.5.3.1. Market
Estimation, 2013 – 2019
8.2.3.5.3.2. Market
Forecast, 2020 – 2028
8.2.3.5.4. Middle
East and Africa
8.2.3.5.4.1. Market
Estimation, 2013 – 2019
8.2.3.5.4.2. Market
Forecast, 2020 – 2028
8.2.3.5.5. Latin
America
8.2.3.5.5.1. Market
Estimation, 2013 – 2019
8.2.3.5.5.2. Market
Forecast, 2020 – 2028
8.2.4. Monoamine
Oxidase Inhibitors (MAOIs)
8.2.4.1. Definition
8.2.4.2. Market
Estimation and Penetration, 2013 – 2019
8.2.4.3. Market
Forecast, 2020 – 2028
8.2.4.4. Compound
Annual Growth Rate (CAGR)
8.2.4.5. Regional
Bifurcation
8.2.4.5.1. North
America
8.2.4.5.1.1. Market
Estimation, 2013 – 2019
8.2.4.5.1.2. Market
Forecast, 2020 – 2028
8.2.4.5.2. Europe
8.2.4.5.2.1. Market
Estimation, 2013 – 2019
8.2.4.5.2.2. Market
Forecast, 2020 – 2028
8.2.4.5.3. Asia
Pacific
8.2.4.5.3.1. Market
Estimation, 2013 – 2019
8.2.4.5.3.2. Market
Forecast, 2020 – 2028
8.2.4.5.4. Middle
East and Africa
8.2.4.5.4.1. Market
Estimation, 2013 – 2019
8.2.4.5.4.2. Market
Forecast, 2020 – 2028
8.2.4.5.5. Latin
America
8.2.4.5.5.1. Market
Estimation, 2013 – 2019
8.2.4.5.5.2. Market
Forecast, 2020 – 2028
8.2.5. Noradrenaline
and Specific Serotoninergic Antidepressants (NaSSAs)
8.2.5.1. Definition
8.2.5.2. Market
Estimation and Penetration, 2013 – 2019
8.2.5.3. Market
Forecast, 2020 – 2028
8.2.5.4. Compound
Annual Growth Rate (CAGR)
8.2.5.5. Regional
Bifurcation
8.2.5.5.1. North
America
8.2.5.5.1.1. Market
Estimation, 2013 – 2019
8.2.5.5.1.2. Market
Forecast, 2020 – 2028
8.2.5.5.2. Europe
8.2.5.5.2.1. Market
Estimation, 2013 – 2019
8.2.5.5.2.2. Market
Forecast, 2020 – 2028
8.2.5.5.3. Asia
Pacific
8.2.5.5.3.1. Market
Estimation, 2013 – 2019
8.2.5.5.3.2. Market
Forecast, 2020 – 2028
8.2.5.5.4. Middle
East and Africa
8.2.5.5.4.1. Market
Estimation, 2013 – 2019
8.2.5.5.4.2. Market
Forecast, 2020 – 2028
8.2.5.5.5. Latin
America
8.2.5.5.5.1. Market
Estimation, 2013 – 2019
8.2.5.5.5.2. Market
Forecast, 2020 – 2028
8.3. Key
Segment for Channeling Investments
8.3.1. By Type
9. Global
Antidepressant Drugs Market Analysis and Forecasts, 2020 – 2028
9.1. Overview
9.2. Global
Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Mode of
Administration
9.2.1. Tablets
and Capsules
9.2.1.1. Definition
9.2.1.2. Market
Estimation and Penetration, 2013 – 2019
9.2.1.3. Market
Forecast, 2020 – 2028
9.2.1.4. Compound
Annual Growth Rate (CAGR)
9.2.1.5. Regional
Bifurcation
9.2.1.5.1. North
America
9.2.1.5.1.1. Market
Estimation, 2013 – 2019
9.2.1.5.1.2. Market
Forecast, 2020 – 2028
9.2.1.5.2. Europe
9.2.1.5.2.1. Market
Estimation, 2013 – 2019
9.2.1.5.2.2. Market
Forecast, 2020 – 2028
9.2.1.5.3. Asia
Pacific
9.2.1.5.3.1. Market
Estimation, 2013 – 2019
9.2.1.5.3.2. Market
Forecast, 2020 – 2028
9.2.1.5.4. Middle
East and Africa
9.2.1.5.4.1. Market
Estimation, 2013 – 2019
9.2.1.5.4.2. Market
Forecast, 2020 – 2028
9.2.1.5.5. Latin
America
9.2.1.5.5.1. Market
Estimation, 2013 – 2019
9.2.1.5.5.2. Market
Forecast, 2020 – 2028
9.2.2. Liquids
9.2.2.1. Definition
9.2.2.2. Market
Estimation and Penetration, 2013 – 2019
9.2.2.3. Market
Forecast, 2020 – 2028
9.2.2.4. Compound
Annual Growth Rate (CAGR)
9.2.2.5. Regional
Bifurcation
9.2.2.5.1. North
America
9.2.2.5.1.1. Market
Estimation, 2013 – 2019
9.2.2.5.1.2. Market
Forecast, 2020 – 2028
9.2.2.5.2. Europe
9.2.2.5.2.1. Market
Estimation, 2013 – 2019
9.2.2.5.2.2. Market
Forecast, 2020 – 2028
9.2.2.5.3. Asia
Pacific
9.2.2.5.3.1. Market
Estimation, 2013 – 2019
9.2.2.5.3.2. Market
Forecast, 2020 – 2028
9.2.2.5.4. Middle
East and Africa
9.2.2.5.4.1. Market
Estimation, 2013 – 2019
9.2.2.5.4.2. Market
Forecast, 2020 – 2028
9.2.2.5.5. Latin
America
9.2.2.5.5.1. Market
Estimation, 2013 – 2019
9.2.2.5.5.2. Market
Forecast, 2020 – 2028
9.2.3. Injections
9.2.3.1. Definition
9.2.3.2. Market
Estimation and Penetration, 2013 – 2019
9.2.3.3. Market
Forecast, 2020 – 2028
9.2.3.4. Compound
Annual Growth Rate (CAGR)
9.2.3.5. Regional
Bifurcation
9.2.3.5.1. North
America
9.2.3.5.1.1. Market
Estimation, 2013 – 2019
9.2.3.5.1.2. Market
Forecast, 2020 – 2028
9.2.3.5.2. Europe
9.2.3.5.2.1. Market
Estimation, 2013 – 2019
9.2.3.5.2.2. Market
Forecast, 2020 – 2028
9.2.3.5.3. Asia
Pacific
9.2.3.5.3.1. Market
Estimation, 2013 – 2019
9.2.3.5.3.2. Market
Forecast, 2020 – 2028
9.2.3.5.4. Middle
East and Africa
9.2.3.5.4.1. Market
Estimation, 2013 – 2019
9.2.3.5.4.2. Market
Forecast, 2020 – 2028
9.2.3.5.5. Latin
America
9.2.3.5.5.1. Market
Estimation, 2013 – 2019
9.2.3.5.5.2. Market
Forecast, 2020 – 2028
9.2.4. Inhalation
9.2.4.1. Definition
9.2.4.2. Market
Estimation and Penetration, 2013 – 2019
9.2.4.3. Market
Forecast, 2020 – 2028
9.2.4.4. Compound
Annual Growth Rate (CAGR)
9.2.4.5. Regional
Bifurcation
9.2.4.5.1. North
America
9.2.4.5.1.1. Market
Estimation, 2013 – 2019
9.2.4.5.1.2. Market
Forecast, 2020 – 2028
9.2.4.5.2. Europe
9.2.4.5.2.1. Market
Estimation, 2013 – 2019
9.2.4.5.2.2. Market
Forecast, 2020 – 2028
9.2.4.5.3. Asia
Pacific
9.2.4.5.3.1. Market
Estimation, 2013 – 2019
9.2.4.5.3.2. Market
Forecast, 2020 – 2028
9.2.4.5.4. Middle
East and Africa
9.2.4.5.4.1. Market
Estimation, 2013 – 2019
9.2.4.5.4.2. Market
Forecast, 2020 – 2028
9.2.4.5.5. Latin
America
9.2.4.5.5.1. Market
Estimation, 2013 – 2019
9.2.4.5.5.2. Market
Forecast, 2020 – 2028
9.2.5. Others
9.2.5.1. Definition
9.2.5.2. Market
Estimation and Penetration, 2013 – 2019
9.2.5.3. Market
Forecast, 2020 – 2028
9.2.5.4. Compound
Annual Growth Rate (CAGR)
9.2.5.5. Regional
Bifurcation
9.2.5.5.1. North
America
9.2.5.5.1.1. Market
Estimation, 2013 – 2019
9.2.5.5.1.2. Market
Forecast, 2020 – 2028
9.2.5.5.2. Europe
9.2.5.5.2.1. Market
Estimation, 2013 – 2019
9.2.5.5.2.2. Market
Forecast, 2020 – 2028
9.2.5.5.3. Asia
Pacific
9.2.5.5.3.1. Market
Estimation, 2013 – 2019
9.2.5.5.3.2. Market
Forecast, 2020 – 2028
9.2.5.5.4. Middle
East and Africa
9.2.5.5.4.1. Market
Estimation, 2013 – 2019
9.2.5.5.4.2. Market
Forecast, 2020 – 2028
9.2.5.5.5. Latin
America
9.2.5.5.5.1. Market
Estimation, 2013 – 2019
9.2.5.5.5.2. Market
Forecast, 2020 – 2028
9.3. Key
Segment for Channeling Investments
9.3.1. By Mode
of Administration
10. Global Antidepressant
Drugs Market Analysis and Forecasts, 2020 – 2028
10.1. Overview
10.2. Global
Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By End-Users
10.2.1. Hospitals
and Clinics
10.2.1.1. Definition
10.2.1.2. Market
Estimation and Penetration, 2013 – 2019
10.2.1.3. Market
Forecast, 2020 – 2028
10.2.1.4. Compound
Annual Growth Rate (CAGR)
10.2.1.5. Regional
Bifurcation
10.2.1.5.1. North
America
10.2.1.5.1.1. Market
Estimation, 2013 – 2019
10.2.1.5.1.2. Market
Forecast, 2020 – 2028
10.2.1.5.2. Europe
10.2.1.5.2.1. Market
Estimation, 2013 – 2019
10.2.1.5.2.2. Market
Forecast, 2020 – 2028
10.2.1.5.3. Asia
Pacific
10.2.1.5.3.1. Market
Estimation, 2013 – 2019
10.2.1.5.3.2. Market
Forecast, 2020 – 2028
10.2.1.5.4. Middle
East and Africa
10.2.1.5.4.1. Market
Estimation, 2013 – 2019
10.2.1.5.4.2. Market
Forecast, 2020 – 2028
10.2.1.5.5. Latin
America
10.2.1.5.5.1. Market
Estimation, 2013 – 2019
10.2.1.5.5.2. Market
Forecast, 2020 – 2028
10.2.2. Pharmacies
10.2.2.1. Definition
10.2.2.2. Market
Estimation and Penetration, 2013 – 2019
10.2.2.3. Market
Forecast, 2020 – 2028
10.2.2.4. Compound
Annual Growth Rate (CAGR)
10.2.2.5. Regional
Bifurcation
10.2.2.5.1. North
America
10.2.2.5.1.1. Market
Estimation, 2013 – 2019
10.2.2.5.1.2. Market
Forecast, 2020 – 2028
10.2.2.5.2. Europe
10.2.2.5.2.1. Market
Estimation, 2013 – 2019
10.2.2.5.2.2. Market
Forecast, 2020 – 2028
10.2.2.5.3. Asia
Pacific
10.2.2.5.3.1. Market
Estimation, 2013 – 2019
10.2.2.5.3.2. Market
Forecast, 2020 – 2028
10.2.2.5.4. Middle
East and Africa
10.2.2.5.4.1. Market
Estimation, 2013 – 2019
10.2.2.5.4.2. Market
Forecast, 2020 – 2028
10.2.2.5.5. Latin
America
10.2.2.5.5.1. Market
Estimation, 2013 – 2019
10.2.2.5.5.2. Market
Forecast, 2020 – 2028
10.2.3. Urgent
Care Centers
10.2.3.1. Definition
10.2.3.2. Market
Estimation and Penetration, 2013 – 2019
10.2.3.3. Market
Forecast, 2020 – 2028
10.2.3.4. Compound
Annual Growth Rate (CAGR)
10.2.3.5. Regional
Bifurcation
10.2.3.5.1. North
America
10.2.3.5.1.1. Market
Estimation, 2013 – 2019
10.2.3.5.1.2. Market
Forecast, 2020 – 2028
10.2.3.5.2. Europe
10.2.3.5.2.1. Market
Estimation, 2013 – 2019
10.2.3.5.2.2. Market
Forecast, 2020 – 2028
10.2.3.5.3. Asia
Pacific
10.2.3.5.3.1. Market
Estimation, 2013 – 2019
10.2.3.5.3.2. Market
Forecast, 2020 – 2028
10.2.3.5.4. Middle
East and Africa
10.2.3.5.4.1. Market
Estimation, 2013 – 2019
10.2.3.5.4.2. Market
Forecast, 2020 – 2028
10.2.3.5.5. Latin
America
10.2.3.5.5.1. Market
Estimation, 2013 – 2019
10.2.3.5.5.2. Market
Forecast, 2020 – 2028
10.2.4. Research
Institutes
10.2.4.1. Definition
10.2.4.2. Market
Estimation and Penetration, 2013 – 2019
10.2.4.3. Market
Forecast, 2020 – 2028
10.2.4.4. Compound
Annual Growth Rate (CAGR)
10.2.4.5. Regional
Bifurcation
10.2.4.5.1. North
America
10.2.4.5.1.1. Market
Estimation, 2013 – 2019
10.2.4.5.1.2. Market
Forecast, 2020 – 2028
10.2.4.5.2. Europe
10.2.4.5.2.1. Market
Estimation, 2013 – 2019
10.2.4.5.2.2. Market
Forecast, 2020 – 2028
10.2.4.5.3. Asia
Pacific
10.2.4.5.3.1. Market
Estimation, 2013 – 2019
10.2.4.5.3.2. Market
Forecast, 2020 – 2028
10.2.4.5.4. Middle
East and Africa
10.2.4.5.4.1. Market
Estimation, 2013 – 2019
10.2.4.5.4.2. Market
Forecast, 2020 – 2028
10.2.4.5.5. Latin
America
10.2.4.5.5.1. Market
Estimation, 2013 – 2019
10.2.4.5.5.2. Market
Forecast, 2020 – 2028
10.2.5. Others
10.2.5.1. Definition
10.2.5.2. Market
Estimation and Penetration, 2013 – 2019
10.2.5.3. Market
Forecast, 2020 – 2028
10.2.5.4. Compound
Annual Growth Rate (CAGR)
10.2.5.5. Regional
Bifurcation
10.2.5.5.1. North
America
10.2.5.5.1.1. Market
Estimation, 2013 – 2019
10.2.5.5.1.2. Market
Forecast, 2020 – 2028
10.2.5.5.2. Europe
10.2.5.5.2.1. Market
Estimation, 2013 – 2019
10.2.5.5.2.2. Market
Forecast, 2020 – 2028
10.2.5.5.3. Asia
Pacific
10.2.5.5.3.1. Market
Estimation, 2013 – 2019
10.2.5.5.3.2. Market
Forecast, 2020 – 2028
10.2.5.5.4. Middle
East and Africa
10.2.5.5.4.1. Market
Estimation, 2013 – 2019
10.2.5.5.4.2. Market
Forecast, 2020 – 2028
10.2.5.5.5. Latin
America
10.2.5.5.5.1. Market
Estimation, 2013 – 2019
10.2.5.5.5.2. Market
Forecast, 2020 – 2028
10.3. Key
Segment for Channeling Investments
10.3.1. By
End-Users
11. Global
Antidepressant Drugs Market Analysis and Forecasts, 2020 – 2028
11.1. Overview
11.2. Global
Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Disorder Type
11.2.1. Major
and Minor Depression
11.2.1.1. Definition
11.2.1.2. Market
Estimation and Penetration, 2013 – 2019
11.2.1.3. Market
Forecast, 2020 – 2028
11.2.1.4. Compound
Annual Growth Rate (CAGR)
11.2.1.5. Regional
Bifurcation
11.2.1.5.1. North
America
11.2.1.5.1.1. Market
Estimation, 2013 – 2019
11.2.1.5.1.2. Market
Forecast, 2020 – 2028
11.2.1.5.2. Europe
11.2.1.5.2.1. Market
Estimation, 2013 – 2019
11.2.1.5.2.2. Market
Forecast, 2020 – 2028
11.2.1.5.3. Asia
Pacific
11.2.1.5.3.1. Market
Estimation, 2013 – 2019
11.2.1.5.3.2. Market
Forecast, 2020 – 2028
11.2.1.5.4. Middle
East and Africa
11.2.1.5.4.1. Market
Estimation, 2013 – 2019
11.2.1.5.4.2. Market
Forecast, 2020 – 2028
11.2.1.5.5. Latin
America
11.2.1.5.5.1. Market
Estimation, 2013 – 2019
11.2.1.5.5.2. Market
Forecast, 2020 – 2028
11.2.2. Obsessive
Compulsive Disorder
11.2.2.1. Definition
11.2.2.2. Market
Estimation and Penetration, 2013 – 2019
11.2.2.3. Market
Forecast, 2020 – 2028
11.2.2.4. Compound
Annual Growth Rate (CAGR)
11.2.2.5. Regional
Bifurcation
11.2.2.5.1. North
America
11.2.2.5.1.1. Market
Estimation, 2013 – 2019
11.2.2.5.1.2. Market
Forecast, 2020 – 2028
11.2.2.5.2. Europe
11.2.2.5.2.1. Market
Estimation, 2013 – 2019
11.2.2.5.2.2. Market
Forecast, 2020 – 2028
11.2.2.5.3. Asia
Pacific
11.2.2.5.3.1. Market
Estimation, 2013 – 2019
11.2.2.5.3.2. Market
Forecast, 2020 – 2028
11.2.2.5.4. Middle
East and Africa
11.2.2.5.4.1. Market
Estimation, 2013 – 2019
11.2.2.5.4.2. Market
Forecast, 2020 – 2028
11.2.2.5.5. Latin
America
11.2.2.5.5.1. Market
Estimation, 2013 – 2019
11.2.2.5.5.2. Market
Forecast, 2020 – 2028
11.2.3. Generalized
Anxiety
11.2.3.1. Definition
11.2.3.2. Market
Estimation and Penetration, 2013 – 2019
11.2.3.3. Market
Forecast, 2020 – 2028
11.2.3.4. Compound
Annual Growth Rate (CAGR)
11.2.3.5. Regional
Bifurcation
11.2.3.5.1. North
America
11.2.3.5.1.1. Market
Estimation, 2013 – 2019
11.2.3.5.1.2. Market
Forecast, 2020 – 2028
11.2.3.5.2. Europe
11.2.3.5.2.1. Market
Estimation, 2013 – 2019
11.2.3.5.2.2. Market
Forecast, 2020 – 2028
11.2.3.5.3. Asia
Pacific
11.2.3.5.3.1. Market
Estimation, 2013 – 2019
11.2.3.5.3.2. Market
Forecast, 2020 – 2028
11.2.3.5.4. Middle
East and Africa
11.2.3.5.4.1. Market
Estimation, 2013 – 2019
11.2.3.5.4.2. Market
Forecast, 2020 – 2028
11.2.3.5.5. Latin
America
11.2.3.5.5.1. Market
Estimation, 2013 – 2019
11.2.3.5.5.2. Market
Forecast, 2020 – 2028
11.2.4. Posttraumatic
Stress (PTSD)
11.2.4.1. Definition
11.2.4.2. Market
Estimation and Penetration, 2013 – 2019
11.2.4.3. Market
Forecast, 2020 – 2028
11.2.4.4. Compound
Annual Growth Rate (CAGR)
11.2.4.5. Regional
Bifurcation
11.2.4.5.1. North
America
11.2.4.5.1.1. Market
Estimation, 2013 – 2019
11.2.4.5.1.2. Market
Forecast, 2020 – 2028
11.2.4.5.2. Europe
11.2.4.5.2.1. Market
Estimation, 2013 – 2019
11.2.4.5.2.2. Market
Forecast, 2020 – 2028
11.2.4.5.3. Asia
Pacific
11.2.4.5.3.1. Market
Estimation, 2013 – 2019
11.2.4.5.3.2. Market
Forecast, 2020 – 2028
11.2.4.5.4. Middle
East and Africa
11.2.4.5.4.1. Market
Estimation, 2013 – 2019
11.2.4.5.4.2. Market
Forecast, 2020 – 2028
11.2.4.5.5. Latin
America
11.2.4.5.5.1. Market
Estimation, 2013 – 2019
11.2.4.5.5.2. Market
Forecast, 2020 – 2028
11.2.5. Social
Anxiety
11.2.5.1. Definition
11.2.5.2. Market
Estimation and Penetration, 2013 – 2019
11.2.5.3. Market
Forecast, 2020 – 2028
11.2.5.4. Compound
Annual Growth Rate (CAGR)
11.2.5.5. Regional
Bifurcation
11.2.5.5.1. North
America
11.2.5.5.1.1. Market
Estimation, 2013 – 2019
11.2.5.5.1.2. Market
Forecast, 2020 – 2028
11.2.5.5.2. Europe
11.2.5.5.2.1. Market
Estimation, 2013 – 2019
11.2.5.5.2.2. Market
Forecast, 2020 – 2028
11.2.5.5.3. Asia
Pacific
11.2.5.5.3.1. Market
Estimation, 2013 – 2019
11.2.5.5.3.2. Market
Forecast, 2020 – 2028
11.2.5.5.4. Middle
East and Africa
11.2.5.5.4.1. Market
Estimation, 2013 – 2019
11.2.5.5.4.2. Market
Forecast, 2020 – 2028
11.2.5.5.5. Latin
America
11.2.5.5.5.1. Market
Estimation, 2013 – 2019
11.2.5.5.5.2. Market
Forecast, 2020 – 2028
11.2.6. Agitation
and Stress
11.2.6.1. Definition
11.2.6.2. Market
Estimation and Penetration, 2013 – 2019
11.2.6.3. Market
Forecast, 2020 – 2028
11.2.6.4. Compound
Annual Growth Rate (CAGR)
11.2.6.5. Regional
Bifurcation
11.2.6.5.1. North
America
11.2.6.5.1.1. Market
Estimation, 2013 – 2019
11.2.6.5.1.2. Market
Forecast, 2020 – 2028
11.2.6.5.2. Europe
11.2.6.5.2.1. Market
Estimation, 2013 – 2019
11.2.6.5.2.2. Market
Forecast, 2020 – 2028
11.2.6.5.3. Asia
Pacific
11.2.6.5.3.1. Market
Estimation, 2013 – 2019
11.2.6.5.3.2. Market
Forecast, 2020 – 2028
11.2.6.5.4. Middle
East and Africa
11.2.6.5.4.1. Market
Estimation, 2013 – 2019
11.2.6.5.4.2. Market
Forecast, 2020 – 2028
11.2.6.5.5. Latin
America
11.2.6.5.5.1. Market
Estimation, 2013 – 2019
11.2.6.5.5.2. Market
Forecast, 2020 – 2028
11.2.7. Bipolar
Disorder
11.2.7.1. Definition
11.2.7.2. Market
Estimation and Penetration, 2013 – 2019
11.2.7.3. Market
Forecast, 2020 – 2028
11.2.7.4. Compound
Annual Growth Rate (CAGR)
11.2.7.5. Regional
Bifurcation
11.2.7.5.1. North
America
11.2.7.5.1.1. Market
Estimation, 2013 – 2019
11.2.7.5.1.2. Market
Forecast, 2020 – 2028
11.2.7.5.2. Europe
11.2.7.5.2.1. Market
Estimation, 2013 – 2019
11.2.7.5.2.2. Market
Forecast, 2020 – 2028
11.2.7.5.3. Asia
Pacific
11.2.7.5.3.1. Market
Estimation, 2013 – 2019
11.2.7.5.3.2. Market
Forecast, 2020 – 2028
11.2.7.5.4. Middle
East and Africa
11.2.7.5.4.1. Market
Estimation, 2013 – 2019
11.2.7.5.4.2. Market
Forecast, 2020 – 2028
11.2.7.5.5. Latin
America
11.2.7.5.5.1. Market
Estimation, 2013 – 2019
11.2.7.5.5.2. Market
Forecast, 2020 – 2028
11.2.8. Others
11.2.8.1. Definition
11.2.8.2. Market
Estimation and Penetration, 2013 – 2019
11.2.8.3. Market
Forecast, 2020 – 2028
11.2.8.4. Compound
Annual Growth Rate (CAGR)
11.2.8.5. Regional
Bifurcation
11.2.8.5.1. North
America
11.2.8.5.1.1. Market
Estimation, 2013 – 2019
11.2.8.5.1.2. Market
Forecast, 2020 – 2028
11.2.8.5.2. Europe
11.2.8.5.2.1. Market
Estimation, 2013 – 2019
11.2.8.5.2.2. Market
Forecast, 2020 – 2028
11.2.8.5.3. Asia
Pacific
11.2.8.5.3.1. Market
Estimation, 2013 – 2019
11.2.8.5.3.2. Market
Forecast, 2020 – 2028
11.2.8.5.4. Middle
East and Africa
11.2.8.5.4.1. Market
Estimation, 2013 – 2019
11.2.8.5.4.2. Market
Forecast, 2020 – 2028
11.2.8.5.5. Latin
America
11.2.8.5.5.1. Market
Estimation, 2013 – 2019
11.2.8.5.5.2. Market
Forecast, 2020 – 2028
11.3. Key
Segment for Channeling Investments
11.3.1. By
Disorder Type
12. North
America Antidepressant Drugs Market Analysis and Forecasts, 2020 - 2028
12.1. Overview
12.1.1. North
America Antidepressant Drugs Market Revenue (US$ Mn)
12.2. North
America Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Type
12.2.1. Serotonin
and Noradrenaline Reuptake Inhibitors (SNRIs)
12.2.2. Selective
Serotonin Reuptake Inhibitors (SSRIs)
12.2.3. Tricyclic
Antidepressants (TCAs)
12.2.4. Monoamine
Oxidase Inhibitors (MAOIs)
12.2.5. Noradrenaline
and Specific Serotoninergic Antidepressants (NaSSAs)
12.3. North
America Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Mode of
Administration
12.3.1. Tablets
and Capsules
12.3.2. Liquids
12.3.3. Injections
12.3.4. Inhalation
12.3.5. Others
12.4. North
America Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By
End-Users
12.4.1. Hospitals
and Clinics
12.4.2. Pharmacies
12.4.3. Urgent
Care Centers
12.4.4. Research
Institutes
12.4.5. Others
12.5. North
America Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Disorder
Type
12.5.1. Major
and Minor Depression
12.5.2. Obsessive
Compulsive Disorder
12.5.3. Generalized
Anxiety
12.5.4. Posttraumatic
Stress (PTSD)
12.5.5. Social
Anxiety
12.5.6. Agitation
and Stress
12.5.7. Bipolar
Disorder
12.5.8. Others
12.6. North
America Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Country
12.6.1. U.S
12.6.1.1. U.S
Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Type
12.6.1.1.1. Serotonin
and Noradrenaline Reuptake Inhibitors (SNRIs)
12.6.1.1.2. Selective
Serotonin Reuptake Inhibitors (SSRIs)
12.6.1.1.3. Tricyclic
Antidepressants (TCAs)
12.6.1.1.4. Monoamine
Oxidase Inhibitors (MAOIs)
12.6.1.1.5. Noradrenaline
and Specific Serotoninergic Antidepressants (NaSSAs)
12.6.1.2. U.S
Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Mode of
Administration
12.6.1.2.1. Tablets
and Capsules
12.6.1.2.2. Liquids
12.6.1.2.3. Injections
12.6.1.2.4. Inhalation
12.6.1.2.5. Others
12.6.1.3. U.S Antidepressant
Drugs Market Revenue (US$ Mn) and Forecasts, By End-Users
12.6.1.3.1. Hospitals
and Clinics
12.6.1.3.2. Pharmacies
12.6.1.3.3. Urgent
Care Centers
12.6.1.3.4. Research
Institutes
12.6.1.3.5. Others
12.6.1.4. U.S
Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Disorder Type
12.6.1.4.1. Major
and Minor Depression
12.6.1.4.2. Obsessive
Compulsive Disorder
12.6.1.4.3. Generalized
Anxiety
12.6.1.4.4. Posttraumatic
Stress (PTSD)
12.6.1.4.5. Social
Anxiety
12.6.1.4.6. Agitation
and Stress
12.6.1.4.7. Bipolar
Disorder
12.6.1.4.8. Others
12.6.2. Canada
12.6.2.1. Canada
Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Type
12.6.2.1.1. Serotonin
and Noradrenaline Reuptake Inhibitors (SNRIs)
12.6.2.1.2. Selective
Serotonin Reuptake Inhibitors (SSRIs)
12.6.2.1.3. Tricyclic
Antidepressants (TCAs)
12.6.2.1.4. Monoamine
Oxidase Inhibitors (MAOIs)
12.6.2.1.5. Noradrenaline
and Specific Serotoninergic Antidepressants (NaSSAs)
12.6.2.2. Canada
Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Mode of
Administration
12.6.2.2.1. Tablets
and Capsules
12.6.2.2.2. Liquids
12.6.2.2.3. Injections
12.6.2.2.4. Inhalation
12.6.2.2.5. Others
12.6.2.3. Canada
Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By End-Users
12.6.2.3.1. Hospitals
and Clinics
12.6.2.3.2. Pharmacies
12.6.2.3.3. Urgent
Care Centers
12.6.2.3.4. Research
Institutes
12.6.2.3.5. Others
12.6.2.4. Canada
Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Disorder Type
12.6.2.4.1. Major
and Minor Depression
12.6.2.4.2. Obsessive
Compulsive Disorder
12.6.2.4.3. Generalized
Anxiety
12.6.2.4.4. Posttraumatic
Stress (PTSD)
12.6.2.4.5. Social
Anxiety
12.6.2.4.6. Agitation
and Stress
12.6.2.4.7. Bipolar
Disorder
12.6.2.4.8. Others
12.6.3. Mexico
12.6.3.1. Mexico
Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Type
12.6.3.1.1. Serotonin
and Noradrenaline Reuptake Inhibitors (SNRIs)
12.6.3.1.2. Selective
Serotonin Reuptake Inhibitors (SSRIs)
12.6.3.1.3. Tricyclic
Antidepressants (TCAs)
12.6.3.1.4. Monoamine
Oxidase Inhibitors (MAOIs)
12.6.3.1.5. Noradrenaline
and Specific Serotoninergic Antidepressants (NaSSAs)
12.6.3.2. Mexico
Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Mode of
Administration
12.6.3.2.1. Tablets
and Capsules
12.6.3.2.2. Liquids
12.6.3.2.3. Injections
12.6.3.2.4. Inhalation
12.6.3.2.5. Others
12.6.3.3. Mexico
Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By End-Users
12.6.3.3.1. Hospitals
and Clinics
12.6.3.3.2. Pharmacies
12.6.3.3.3. Urgent
Care Centers
12.6.3.3.4. Research
Institutes
12.6.3.3.5. Others
12.6.3.4. Mexico
Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Disorder Type
12.6.3.4.1. Major
and Minor Depression
12.6.3.4.2. Obsessive
Compulsive Disorder
12.6.3.4.3. Generalized
Anxiety
12.6.3.4.4. Posttraumatic
Stress (PTSD)
12.6.3.4.5. Social
Anxiety
12.6.3.4.6. Agitation
and Stress
12.6.3.4.7. Bipolar
Disorder
12.6.3.4.8. Others
12.6.4. Rest of
North America
12.6.4.1. Rest
of North America Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By
Type
12.6.4.1.1. Serotonin
and Noradrenaline Reuptake Inhibitors (SNRIs)
12.6.4.1.2. Selective
Serotonin Reuptake Inhibitors (SSRIs)
12.6.4.1.3. Tricyclic
Antidepressants (TCAs)
12.6.4.1.4. Monoamine
Oxidase Inhibitors (MAOIs)
12.6.4.1.5. Noradrenaline
and Specific Serotoninergic Antidepressants (NaSSAs)
12.6.4.2. Rest
of North America Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By
Mode of Administration
12.6.4.2.1. Tablets
and Capsules
12.6.4.2.2. Liquids
12.6.4.2.3. Injections
12.6.4.2.4. Inhalation
12.6.4.2.5. Others
12.6.4.3. Rest
of North America Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By
End-Users
12.6.4.3.1. Hospitals
and Clinics
12.6.4.3.2. Pharmacies
12.6.4.3.3. Urgent
Care Centers
12.6.4.3.4. Research
Institutes
12.6.4.3.5. Others
12.6.4.4. Rest
of North America Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By
Disorder Type
12.6.4.4.1. Major
and Minor Depression
12.6.4.4.2. Obsessive
Compulsive Disorder
12.6.4.4.3. Generalized
Anxiety
12.6.4.4.4. Posttraumatic
Stress (PTSD)
12.6.4.4.5. Social
Anxiety
12.6.4.4.6. Agitation
and Stress
12.6.4.4.7. Bipolar
Disorder
12.6.4.4.8. Others
12.7. Key
Segment for Channeling Investments
12.7.1. By
Country
12.7.2. By Type
12.7.3. By Mode
of Administration
12.7.4. By
End-Users
12.7.5. By
Disorder Type
13. Europe
Antidepressant Drugs Market Analysis and Forecasts, 2020 - 2028
13.1. Overview
13.1.1. Europe
Antidepressant Drugs Market Revenue (US$ Mn)
13.2. Europe
Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Type
13.2.1. Serotonin
and Noradrenaline Reuptake Inhibitors (SNRIs)
13.2.2. Selective
Serotonin Reuptake Inhibitors (SSRIs)
13.2.3. Tricyclic
Antidepressants (TCAs)
13.2.4. Monoamine
Oxidase Inhibitors (MAOIs)
13.2.5. Noradrenaline
and Specific Serotoninergic Antidepressants (NaSSAs)
13.3. Europe
Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Mode of
Administration
13.3.1. Tablets
and Capsules
13.3.2. Liquids
13.3.3. Injections
13.3.4. Inhalation
13.3.5. Others
13.4. Europe
Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By End-Users
13.4.1. Hospitals
and Clinics
13.4.2. Pharmacies
13.4.3. Urgent
Care Centers
13.4.4. Research
Institutes
13.4.5. Others
13.5. Europe
Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Disorder Type
13.5.1. Major
and Minor Depression
13.5.2. Obsessive
Compulsive Disorder
13.5.3. Generalized
Anxiety
13.5.4. Posttraumatic
Stress (PTSD)
13.5.5. Social
Anxiety
13.5.6. Agitation
and Stress
13.5.7. Bipolar
Disorder
13.5.8. Others
13.6. Europe
Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Country
13.6.1. France
13.6.1.1. France
Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Type
13.6.1.1.1. Serotonin
and Noradrenaline Reuptake Inhibitors (SNRIs)
13.6.1.1.2. Selective
Serotonin Reuptake Inhibitors (SSRIs)
13.6.1.1.3. Tricyclic
Antidepressants (TCAs)
13.6.1.1.4. Monoamine
Oxidase Inhibitors (MAOIs)
13.6.1.1.5. Noradrenaline
and Specific Serotoninergic Antidepressants (NaSSAs)
13.6.1.2. France
Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Mode of
Administration
13.6.1.2.1. Tablets
and Capsules
13.6.1.2.2. Liquids
13.6.1.2.3. Injections
13.6.1.2.4. Inhalation
13.6.1.2.5. Others
13.6.1.3. France
Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By End-Users
13.6.1.3.1. Hospitals
and Clinics
13.6.1.3.2. Pharmacies
13.6.1.3.3. Urgent
Care Centers
13.6.1.3.4. Research
Institutes
13.6.1.3.5. Others
13.6.1.4. France
Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Disorder Type
13.6.1.4.1. Major
and Minor Depression
13.6.1.4.2. Obsessive
Compulsive Disorder
13.6.1.4.3. Generalized
Anxiety
13.6.1.4.4. Posttraumatic
Stress (PTSD)
13.6.1.4.5. Social
Anxiety
13.6.1.4.6. Agitation
and Stress
13.6.1.4.7. Bipolar
Disorder
13.6.1.4.8. Others
13.6.2. The UK
13.6.2.1. The
UK Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Type
13.6.2.1.1. Serotonin
and Noradrenaline Reuptake Inhibitors (SNRIs)
13.6.2.1.2. Selective
Serotonin Reuptake Inhibitors (SSRIs)
13.6.2.1.3. Tricyclic
Antidepressants (TCAs)
13.6.2.1.4. Monoamine
Oxidase Inhibitors (MAOIs)
13.6.2.1.5. Noradrenaline
and Specific Serotoninergic Antidepressants (NaSSAs)
13.6.2.2. The
UK Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Mode of
Administration
13.6.2.2.1. Tablets
and Capsules
13.6.2.2.2. Liquids
13.6.2.2.3. Injections
13.6.2.2.4. Inhalation
13.6.2.2.5. Others
13.6.2.3. The
UK Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By End-Users
13.6.2.3.1. Hospitals
and Clinics
13.6.2.3.2. Pharmacies
13.6.2.3.3. Urgent
Care Centers
13.6.2.3.4. Research
Institutes
13.6.2.3.5. Others
13.6.2.4. The
UK Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Disorder Type
13.6.2.4.1. Major
and Minor Depression
13.6.2.4.2. Obsessive
Compulsive Disorder
13.6.2.4.3. Generalized
Anxiety
13.6.2.4.4. Posttraumatic
Stress (PTSD)
13.6.2.4.5. Social
Anxiety
13.6.2.4.6. Agitation
and Stress
13.6.2.4.7. Bipolar
Disorder
13.6.2.4.8. Others
13.6.3. Spain
13.6.3.1. Spain
Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Type
13.6.3.1.1. Serotonin
and Noradrenaline Reuptake Inhibitors (SNRIs)
13.6.3.1.2. Selective
Serotonin Reuptake Inhibitors (SSRIs)
13.6.3.1.3. Tricyclic
Antidepressants (TCAs)
13.6.3.1.4. Monoamine
Oxidase Inhibitors (MAOIs)
13.6.3.1.5. Noradrenaline
and Specific Serotoninergic Antidepressants (NaSSAs)
13.6.3.2. Spain
Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Mode of
Administration
13.6.3.2.1. Tablets
and Capsules
13.6.3.2.2. Liquids
13.6.3.2.3. Injections
13.6.3.2.4. Inhalation
13.6.3.2.5. Others
13.6.3.3. Spain
Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By End-Users
13.6.3.3.1. Hospitals
and Clinics
13.6.3.3.2. Pharmacies
13.6.3.3.3. Urgent
Care Centers
13.6.3.3.4. Research
Institutes
13.6.3.3.5. Others
13.6.3.4. Spain
Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Disorder Type
13.6.3.4.1. Major
and Minor Depression
13.6.3.4.2. Obsessive
Compulsive Disorder
13.6.3.4.3. Generalized
Anxiety
13.6.3.4.4. Posttraumatic
Stress (PTSD)
13.6.3.4.5. Social
Anxiety
13.6.3.4.6. Agitation
and Stress
13.6.3.4.7. Bipolar
Disorder
13.6.3.4.8. Others
13.6.4. Germany
13.6.4.1. Germany
Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Type
13.6.4.1.1. Serotonin
and Noradrenaline Reuptake Inhibitors (SNRIs)
13.6.4.1.2. Selective
Serotonin Reuptake Inhibitors (SSRIs)
13.6.4.1.3. Tricyclic
Antidepressants (TCAs)
13.6.4.1.4. Monoamine
Oxidase Inhibitors (MAOIs)
13.6.4.1.5. Noradrenaline
and Specific Serotoninergic Antidepressants (NaSSAs)
13.6.4.2. Germany
Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Mode of Administration
13.6.4.2.1. Tablets
and Capsules
13.6.4.2.2. Liquids
13.6.4.2.3. Injections
13.6.4.2.4. Inhalation
13.6.4.2.5. Others
13.6.4.3. Germany
Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By End-Users
13.6.4.3.1. Hospitals
and Clinics
13.6.4.3.2. Pharmacies
13.6.4.3.3. Urgent
Care Centers
13.6.4.3.4. Research
Institutes
13.6.4.3.5. Others
13.6.4.4. Germany
Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Disorder Type
13.6.4.4.1. Major
and Minor Depression
13.6.4.4.2. Obsessive
Compulsive Disorder
13.6.4.4.3. Generalized
Anxiety
13.6.4.4.4. Posttraumatic
Stress (PTSD)
13.6.4.4.5. Social
Anxiety
13.6.4.4.6. Agitation
and Stress
13.6.4.4.7. Bipolar
Disorder
13.6.4.4.8. Others
13.6.5. Italy
13.6.5.1. Italy
Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Type
13.6.5.1.1. Serotonin
and Noradrenaline Reuptake Inhibitors (SNRIs)
13.6.5.1.2. Selective
Serotonin Reuptake Inhibitors (SSRIs)
13.6.5.1.3. Tricyclic
Antidepressants (TCAs)
13.6.5.1.4. Monoamine
Oxidase Inhibitors (MAOIs)
13.6.5.1.5. Noradrenaline
and Specific Serotoninergic Antidepressants (NaSSAs)
13.6.5.2. Italy
Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Mode of
Administration
13.6.5.2.1. Tablets
and Capsules
13.6.5.2.2. Liquids
13.6.5.2.3. Injections
13.6.5.2.4. Inhalation
13.6.5.2.5. Others
13.6.5.3. Italy
Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By End-Users
13.6.5.3.1. Hospitals
and Clinics
13.6.5.3.2. Pharmacies
13.6.5.3.3. Urgent
Care Centers
13.6.5.3.4. Research
Institutes
13.6.5.3.5. Others
13.6.5.4. Italy
Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Disorder Type
13.6.5.4.1. Major
and Minor Depression
13.6.5.4.2. Obsessive
Compulsive Disorder
13.6.5.4.3. Generalized
Anxiety
13.6.5.4.4. Posttraumatic
Stress (PTSD)
13.6.5.4.5. Social
Anxiety
13.6.5.4.6. Agitation
and Stress
13.6.5.4.7. Bipolar
Disorder
13.6.5.4.8. Others
13.6.6. Nordic
Countries
13.6.6.1. Nordic
Countries Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Type
13.6.6.1.1. Serotonin
and Noradrenaline Reuptake Inhibitors (SNRIs)
13.6.6.1.2. Selective
Serotonin Reuptake Inhibitors (SSRIs)
13.6.6.1.3. Tricyclic
Antidepressants (TCAs)
13.6.6.1.4. Monoamine
Oxidase Inhibitors (MAOIs)
13.6.6.1.5. Noradrenaline
and Specific Serotoninergic Antidepressants (NaSSAs)
13.6.6.2. Nordic
Countries Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Mode
of Administration
13.6.6.2.1. Tablets
and Capsules
13.6.6.2.2. Liquids
13.6.6.2.3. Injections
13.6.6.2.4. Inhalation
13.6.6.2.5. Others
13.6.6.3. Nordic
Countries Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By
End-Users
13.6.6.3.1. Hospitals
and Clinics
13.6.6.3.2. Pharmacies
13.6.6.3.3. Urgent
Care Centers
13.6.6.3.4. Research
Institutes
13.6.6.3.5. Others
13.6.6.4. Nordic
Countries Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By
Disorder Type
13.6.6.4.1. Major
and Minor Depression
13.6.6.4.2. Obsessive
Compulsive Disorder
13.6.6.4.3. Generalized
Anxiety
13.6.6.4.4. Posttraumatic
Stress (PTSD)
13.6.6.4.5. Social
Anxiety
13.6.6.4.6. Agitation
and Stress
13.6.6.4.7. Bipolar
Disorder
13.6.6.4.8. Others
13.6.6.5. Nordic
Countries Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By
Country
13.6.6.5.1. Denmark
13.6.6.5.2. Finland
13.6.6.5.3. Iceland
13.6.6.5.4. Sweden
13.6.6.5.5. Norway
13.6.7. Benelux
Union
13.6.7.1. Benelux
Union Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Type
13.6.7.1.1. Serotonin
and Noradrenaline Reuptake Inhibitors (SNRIs)
13.6.7.1.2. Selective
Serotonin Reuptake Inhibitors (SSRIs)
13.6.7.1.3. Tricyclic
Antidepressants (TCAs)
13.6.7.1.4. Monoamine
Oxidase Inhibitors (MAOIs)
13.6.7.1.5. Noradrenaline
and Specific Serotoninergic Antidepressants (NaSSAs)
13.6.7.2. Benelux
Union Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Mode of
Administration
13.6.7.2.1. Tablets
and Capsules
13.6.7.2.2. Liquids
13.6.7.2.3. Injections
13.6.7.2.4. Inhalation
13.6.7.2.5. Others
13.6.7.3. Benelux
Union Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By End-Users
13.6.7.3.1. Hospitals
and Clinics
13.6.7.3.2. Pharmacies
13.6.7.3.3. Urgent
Care Centers
13.6.7.3.4. Research
Institutes
13.6.7.3.5. Others
13.6.7.4. Benelux
Union Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Disorder
Type
13.6.7.4.1. Major
and Minor Depression
13.6.7.4.2. Obsessive
Compulsive Disorder
13.6.7.4.3. Generalized
Anxiety
13.6.7.4.4. Posttraumatic
Stress (PTSD)
13.6.7.4.5. Social
Anxiety
13.6.7.4.6. Agitation
and Stress
13.6.7.4.7. Bipolar
Disorder
13.6.7.4.8. Others
13.6.7.5. Benelux
Union Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Country
13.6.7.5.1. Belgium
13.6.7.5.2. The
Netherlands
13.6.7.5.3. Luxembourg
13.6.8. Rest of
Europe
13.6.8.1. Rest
of Europe Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Type
13.6.8.1.1. Serotonin
and Noradrenaline Reuptake Inhibitors (SNRIs)
13.6.8.1.2. Selective
Serotonin Reuptake Inhibitors (SSRIs)
13.6.8.1.3. Tricyclic
Antidepressants (TCAs)
13.6.8.1.4. Monoamine
Oxidase Inhibitors (MAOIs)
13.6.8.1.5. Noradrenaline
and Specific Serotoninergic Antidepressants (NaSSAs)
13.6.8.2. Rest
of Europe Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Mode
of Administration
13.6.8.2.1. Tablets
and Capsules
13.6.8.2.2. Liquids
13.6.8.2.3. Injections
13.6.8.2.4. Inhalation
13.6.8.2.5. Others
13.6.8.3. Rest
of Europe Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By
End-Users
13.6.8.3.1. Hospitals
and Clinics
13.6.8.3.2. Pharmacies
13.6.8.3.3. Urgent
Care Centers
13.6.8.3.4. Research
Institutes
13.6.8.3.5. Others
13.6.8.4. Rest
of Europe Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By
Disorder Type
13.6.8.4.1. Major
and Minor Depression
13.6.8.4.2. Obsessive
Compulsive Disorder
13.6.8.4.3. Generalized
Anxiety
13.6.8.4.4. Posttraumatic
Stress (PTSD)
13.6.8.4.5. Social
Anxiety
13.6.8.4.6. Agitation
and Stress
13.6.8.4.7. Bipolar
Disorder
13.6.8.4.8. Others
13.7. Key
Segment for Channeling Investments
13.7.1. By
Country
13.7.2. By Type
13.7.3. By Mode
of Administration
13.7.4. By
End-Users
13.7.5. By
Disorder Type
14. Asia
Pacific Antidepressant Drugs Market Analysis and Forecasts, 2020 - 2028
14.1. Overview
14.1.1. Asia
Pacific Antidepressant Drugs Market Revenue (US$ Mn)
14.2. Asia
Pacific Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Type
14.2.1. Serotonin
and Noradrenaline Reuptake Inhibitors (SNRIs)
14.2.2. Selective
Serotonin Reuptake Inhibitors (SSRIs)
14.2.3. Tricyclic
Antidepressants (TCAs)
14.2.4. Monoamine
Oxidase Inhibitors (MAOIs)
14.2.5. Noradrenaline
and Specific Serotoninergic Antidepressants (NaSSAs)
14.3. Asia
Pacific Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Mode of
Administration
14.3.1. Tablets
and Capsules
14.3.2. Liquids
14.3.3. Injections
14.3.4. Inhalation
14.3.5. Others
14.4. Asia
Pacific Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By
End-Users
14.4.1. Hospitals
and Clinics
14.4.2. Pharmacies
14.4.3. Urgent
Care Centers
14.4.4. Research
Institutes
14.4.5. Others
14.5. Asia
Pacific Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Disorder
Type
14.5.1. Major
and Minor Depression
14.5.2. Obsessive
Compulsive Disorder
14.5.3. Generalized
Anxiety
14.5.4. Posttraumatic
Stress (PTSD)
14.5.5. Social
Anxiety
14.5.6. Agitation
and Stress
14.5.7. Bipolar
Disorder
14.5.8. Others
14.6. Asia
Pacific Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Country
14.6.1. China
14.6.1.1. China
Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Type
14.6.1.1.1. Serotonin
and Noradrenaline Reuptake Inhibitors (SNRIs)
14.6.1.1.2. Selective
Serotonin Reuptake Inhibitors (SSRIs)
14.6.1.1.3. Tricyclic
Antidepressants (TCAs)
14.6.1.1.4. Monoamine
Oxidase Inhibitors (MAOIs)
14.6.1.1.5. Noradrenaline
and Specific Serotoninergic Antidepressants (NaSSAs)
14.6.1.2. China
Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Mode of
Administration
14.6.1.2.1. Tablets
and Capsules
14.6.1.2.2. Liquids
14.6.1.2.3. Injections
14.6.1.2.4. Inhalation
14.6.1.2.5. Others
14.6.1.3. China
Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By End-Users
14.6.1.3.1. Hospitals
and Clinics
14.6.1.3.2. Pharmacies
14.6.1.3.3. Urgent
Care Centers
14.6.1.3.4. Research
Institutes
14.6.1.3.5. Others
14.6.1.4. China
Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Disorder Type
14.6.1.4.1. Major
and Minor Depression
14.6.1.4.2. Obsessive
Compulsive Disorder
14.6.1.4.3. Generalized
Anxiety
14.6.1.4.4. Posttraumatic
Stress (PTSD)
14.6.1.4.5. Social
Anxiety
14.6.1.4.6. Agitation
and Stress
14.6.1.4.7. Bipolar
Disorder
14.6.1.4.8. Others
14.6.2. Japan
14.6.2.1. Japan
Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Type
14.6.2.1.1. Serotonin
and Noradrenaline Reuptake Inhibitors (SNRIs)
14.6.2.1.2. Selective
Serotonin Reuptake Inhibitors (SSRIs)
14.6.2.1.3. Tricyclic
Antidepressants (TCAs)
14.6.2.1.4. Monoamine
Oxidase Inhibitors (MAOIs)
14.6.2.1.5. Noradrenaline
and Specific Serotoninergic Antidepressants (NaSSAs)
14.6.2.2. Japan
Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Mode of
Administration
14.6.2.2.1. Tablets
and Capsules
14.6.2.2.2. Liquids
14.6.2.2.3. Injections
14.6.2.2.4. Inhalation
14.6.2.2.5. Others
14.6.2.3. Japan
Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By End-Users
14.6.2.3.1. Hospitals
and Clinics
14.6.2.3.2. Pharmacies
14.6.2.3.3. Urgent
Care Centers
14.6.2.3.4. Research
Institutes
14.6.2.3.5. Others
14.6.2.4. Japan
Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Disorder Type
14.6.2.4.1. Major
and Minor Depression
14.6.2.4.2. Obsessive
Compulsive Disorder
14.6.2.4.3. Generalized
Anxiety
14.6.2.4.4. Posttraumatic
Stress (PTSD)
14.6.2.4.5. Social
Anxiety
14.6.2.4.6. Agitation
and Stress
14.6.2.4.7. Bipolar
Disorder
14.6.2.4.8. Others
14.6.3. India
14.6.3.1. India
Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Type
14.6.3.1.1. Serotonin
and Noradrenaline Reuptake Inhibitors (SNRIs)
14.6.3.1.2. Selective
Serotonin Reuptake Inhibitors (SSRIs)
14.6.3.1.3. Tricyclic
Antidepressants (TCAs)
14.6.3.1.4. Monoamine
Oxidase Inhibitors (MAOIs)
14.6.3.1.5. Noradrenaline
and Specific Serotoninergic Antidepressants (NaSSAs)
14.6.3.2. India
Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Mode of
Administration
14.6.3.2.1. Tablets
and Capsules
14.6.3.2.2. Liquids
14.6.3.2.3. Injections
14.6.3.2.4. Inhalation
14.6.3.2.5. Others
14.6.3.3. India
Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By End-Users
14.6.3.3.1. Hospitals
and Clinics
14.6.3.3.2. Pharmacies
14.6.3.3.3. Urgent
Care Centers
14.6.3.3.4. Research
Institutes
14.6.3.3.5. Others
14.6.3.4. India
Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Disorder Type
14.6.3.4.1. Major
and Minor Depression
14.6.3.4.2. Obsessive
Compulsive Disorder
14.6.3.4.3. Generalized
Anxiety
14.6.3.4.4. Posttraumatic
Stress (PTSD)
14.6.3.4.5. Social
Anxiety
14.6.3.4.6. Agitation
and Stress
14.6.3.4.7. Bipolar
Disorder
14.6.3.4.8. Others
14.6.4. New
Zealand
14.6.4.1. New
Zealand Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Type
14.6.4.1.1. Serotonin
and Noradrenaline Reuptake Inhibitors (SNRIs)
14.6.4.1.2. Selective
Serotonin Reuptake Inhibitors (SSRIs)
14.6.4.1.3. Tricyclic
Antidepressants (TCAs)
14.6.4.1.4. Monoamine
Oxidase Inhibitors (MAOIs)
14.6.4.1.5. Noradrenaline
and Specific Serotoninergic Antidepressants (NaSSAs)
14.6.4.2. New
Zealand Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Mode of Administration
14.6.4.2.1. Tablets
and Capsules
14.6.4.2.2. Liquids
14.6.4.2.3. Injections
14.6.4.2.4. Inhalation
14.6.4.2.5. Others
14.6.4.3. New
Zealand Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By
End-Users
14.6.4.3.1. Hospitals
and Clinics
14.6.4.3.2. Pharmacies
14.6.4.3.3. Urgent
Care Centers
14.6.4.3.4. Research
Institutes
14.6.4.3.5. Others
14.6.4.4. New
Zealand Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Disorder
Type
14.6.4.4.1. Major
and Minor Depression
14.6.4.4.2. Obsessive
Compulsive Disorder
14.6.4.4.3. Generalized
Anxiety
14.6.4.4.4. Posttraumatic
Stress (PTSD)
14.6.4.4.5. Social
Anxiety
14.6.4.4.6. Agitation
and Stress
14.6.4.4.7. Bipolar
Disorder
14.6.4.4.8. Others
14.6.5. Australia
14.6.5.1. Australia
Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Type
14.6.5.1.1. Serotonin
and Noradrenaline Reuptake Inhibitors (SNRIs)
14.6.5.1.2. Selective
Serotonin Reuptake Inhibitors (SSRIs)
14.6.5.1.3. Tricyclic
Antidepressants (TCAs)
14.6.5.1.4. Monoamine
Oxidase Inhibitors (MAOIs)
14.6.5.1.5. Noradrenaline
and Specific Serotoninergic Antidepressants (NaSSAs)
14.6.5.2. Australia
Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Mode of
Administration
14.6.5.2.1. Tablets
and Capsules
14.6.5.2.2. Liquids
14.6.5.2.3. Injections
14.6.5.2.4. Inhalation
14.6.5.2.5. Others
14.6.5.3. Australia
Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By End-Users
14.6.5.3.1. Hospitals
and Clinics
14.6.5.3.2. Pharmacies
14.6.5.3.3. Urgent
Care Centers
14.6.5.3.4. Research
Institutes
14.6.5.3.5. Others
14.6.5.4. Australia
Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Disorder Type
14.6.5.4.1. Major
and Minor Depression
14.6.5.4.2. Obsessive
Compulsive Disorder
14.6.5.4.3. Generalized
Anxiety
14.6.5.4.4. Posttraumatic
Stress (PTSD)
14.6.5.4.5. Social
Anxiety
14.6.5.4.6. Agitation
and Stress
14.6.5.4.7. Bipolar
Disorder
14.6.5.4.8. Others
14.6.6. South
Korea
14.6.6.1. South
Korea Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Type
14.6.6.1.1. Serotonin
and Noradrenaline Reuptake Inhibitors (SNRIs)
14.6.6.1.2. Selective
Serotonin Reuptake Inhibitors (SSRIs)
14.6.6.1.3. Tricyclic
Antidepressants (TCAs)
14.6.6.1.4. Monoamine
Oxidase Inhibitors (MAOIs)
14.6.6.1.5. Noradrenaline
and Specific Serotoninergic Antidepressants (NaSSAs)
14.6.6.2. South
Korea Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Mode of
Administration
14.6.6.2.1. Tablets
and Capsules
14.6.6.2.2. Liquids
14.6.6.2.3. Injections
14.6.6.2.4. Inhalation
14.6.6.2.5. Others
14.6.6.3. South
Korea Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By End-Users
14.6.6.3.1. Hospitals
and Clinics
14.6.6.3.2. Pharmacies
14.6.6.3.3. Urgent
Care Centers
14.6.6.3.4. Research
Institutes
14.6.6.3.5. Others
14.6.6.4. South
Korea Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Disorder
Type
14.6.6.4.1. Major
and Minor Depression
14.6.6.4.2. Obsessive
Compulsive Disorder
14.6.6.4.3. Generalized
Anxiety
14.6.6.4.4. Posttraumatic
Stress (PTSD)
14.6.6.4.5. Social
Anxiety
14.6.6.4.6. Agitation
and Stress
14.6.6.4.7. Bipolar
Disorder
14.6.6.4.8. Others
14.6.7. Southeast
Asia
14.6.7.1. Southeast
Asia Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Type
14.6.7.1.1. Serotonin
and Noradrenaline Reuptake Inhibitors (SNRIs)
14.6.7.1.2. Selective
Serotonin Reuptake Inhibitors (SSRIs)
14.6.7.1.3. Tricyclic
Antidepressants (TCAs)
14.6.7.1.4. Monoamine
Oxidase Inhibitors (MAOIs)
14.6.7.1.5. Noradrenaline
and Specific Serotoninergic Antidepressants (NaSSAs)
14.6.7.2. Southeast
Asia Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Mode of
Administration
14.6.7.2.1. Tablets
and Capsules
14.6.7.2.2. Liquids
14.6.7.2.3. Injections
14.6.7.2.4. Inhalation
14.6.7.2.5. Others
14.6.7.3. Southeast
Asia Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By End-Users
14.6.7.3.1. Hospitals
and Clinics
14.6.7.3.2. Pharmacies
14.6.7.3.3. Urgent
Care Centers
14.6.7.3.4. Research
Institutes
14.6.7.3.5. Others
14.6.7.4. Southeast
Asia Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Disorder
Type
14.6.7.4.1. Major
and Minor Depression
14.6.7.4.2. Obsessive
Compulsive Disorder
14.6.7.4.3. Generalized
Anxiety
14.6.7.4.4. Posttraumatic
Stress (PTSD)
14.6.7.4.5. Social
Anxiety
14.6.7.4.6. Agitation
and Stress
14.6.7.4.7. Bipolar
Disorder
14.6.7.4.8. Others
14.6.7.5. Southeast
Asia Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Country
14.6.7.5.1. Indonesia
14.6.7.5.2. Thailand
14.6.7.5.3. Malaysia
14.6.7.5.4. Singapore
14.6.7.5.5. Rest
of Southeast Asia
14.6.8. Rest of
Asia Pacific
14.6.8.1. Rest
of Asia Pacific Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By
Type
14.6.8.1.1. Serotonin
and Noradrenaline Reuptake Inhibitors (SNRIs)
14.6.8.1.2. Selective
Serotonin Reuptake Inhibitors (SSRIs)
14.6.8.1.3. Tricyclic
Antidepressants (TCAs)
14.6.8.1.4. Monoamine
Oxidase Inhibitors (MAOIs)
14.6.8.1.5. Noradrenaline
and Specific Serotoninergic Antidepressants (NaSSAs)
14.6.8.2. Rest
of Asia Pacific Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By
Mode of Administration
14.6.8.2.1. Tablets
and Capsules
14.6.8.2.2. Liquids
14.6.8.2.3. Injections
14.6.8.2.4. Inhalation
14.6.8.2.5. Others
14.6.8.3. Rest
of Asia Pacific Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By
End-Users
14.6.8.3.1. Hospitals
and Clinics
14.6.8.3.2. Pharmacies
14.6.8.3.3. Urgent
Care Centers
14.6.8.3.4. Research
Institutes
14.6.8.3.5. Others
14.6.8.4. Rest
of Asia Pacific Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By
Disorder Type
14.6.8.4.1. Major
and Minor Depression
14.6.8.4.2. Obsessive
Compulsive Disorder
14.6.8.4.3. Generalized
Anxiety
14.6.8.4.4. Posttraumatic
Stress (PTSD)
14.6.8.4.5. Social
Anxiety
14.6.8.4.6. Agitation
and Stress
14.6.8.4.7. Bipolar
Disorder
14.6.8.4.8. Others
14.7. Key
Segment for Channeling Investments
14.7.1. By
Country
14.7.2. By Type
14.7.3. By Mode
of Administration
14.7.4. By
End-Users
14.7.5. By
Disorder Type
15. Middle
East and Africa Antidepressant Drugs Market Analysis and Forecasts, 2020 - 2028
15.1. Overview
15.1.1. Middle
East and Africa Antidepressant Drugs Market Revenue (US$ Mn)
15.2. Middle
East and Africa Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By
Type
15.2.1. Serotonin
and Noradrenaline Reuptake Inhibitors (SNRIs)
15.2.2. Selective
Serotonin Reuptake Inhibitors (SSRIs)
15.2.3. Tricyclic
Antidepressants (TCAs)
15.2.4. Monoamine
Oxidase Inhibitors (MAOIs)
15.2.5. Noradrenaline
and Specific Serotoninergic Antidepressants (NaSSAs)
15.3. Middle
East and Africa Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By
Mode of Administration
15.3.1. Tablets
and Capsules
15.3.2. Liquids
15.3.3. Injections
15.3.4. Inhalation
15.3.5. Others
15.4. Middle
East and Africa Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By
End-Users
15.4.1. Hospitals
and Clinics
15.4.2. Pharmacies
15.4.3. Urgent
Care Centers
15.4.4. Research
Institutes
15.4.5. Others
15.5. Middle
East and Africa Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By
Disorder Type
15.5.1. Major
and Minor Depression
15.5.2. Obsessive
Compulsive Disorder
15.5.3. Generalized
Anxiety
15.5.4. Posttraumatic
Stress (PTSD)
15.5.5. Social
Anxiety
15.5.6. Agitation
and Stress
15.5.7. Bipolar
Disorder
15.5.8. Others
15.6. Middle
East and Africa Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By
Country
15.6.1. Saudi
Arabia
15.6.1.1. Saudi
Arabia Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Type
15.6.1.1.1. Serotonin
and Noradrenaline Reuptake Inhibitors (SNRIs)
15.6.1.1.2. Selective
Serotonin Reuptake Inhibitors (SSRIs)
15.6.1.1.3. Tricyclic
Antidepressants (TCAs)
15.6.1.1.4. Monoamine
Oxidase Inhibitors (MAOIs)
15.6.1.1.5. Noradrenaline
and Specific Serotoninergic Antidepressants (NaSSAs)
15.6.1.2. Saudi
Arabia Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Mode of
Administration
15.6.1.2.1. Tablets
and Capsules
15.6.1.2.2. Liquids
15.6.1.2.3. Injections
15.6.1.2.4. Inhalation
15.6.1.2.5. Others
15.6.1.3. Saudi
Arabia Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By End-Users
15.6.1.3.1. Hospitals
and Clinics
15.6.1.3.2. Pharmacies
15.6.1.3.3. Urgent
Care Centers
15.6.1.3.4. Research
Institutes
15.6.1.3.5. Others
15.6.1.4. Saudi
Arabia Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Disorder
Type
15.6.1.4.1. Major
and Minor Depression
15.6.1.4.2. Obsessive
Compulsive Disorder
15.6.1.4.3. Generalized
Anxiety
15.6.1.4.4. Posttraumatic
Stress (PTSD)
15.6.1.4.5. Social
Anxiety
15.6.1.4.6. Agitation
and Stress
15.6.1.4.7. Bipolar
Disorder
15.6.1.4.8. Others
15.6.2. UAE
15.6.2.1. UAE
Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Type
15.6.2.1.1. Serotonin
and Noradrenaline Reuptake Inhibitors (SNRIs)
15.6.2.1.2. Selective
Serotonin Reuptake Inhibitors (SSRIs)
15.6.2.1.3. Tricyclic
Antidepressants (TCAs)
15.6.2.1.4. Monoamine
Oxidase Inhibitors (MAOIs)
15.6.2.1.5. Noradrenaline
and Specific Serotoninergic Antidepressants (NaSSAs)
15.6.2.2. UAE
Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Mode of
Administration
15.6.2.2.1. Tablets
and Capsules
15.6.2.2.2. Liquids
15.6.2.2.3. Injections
15.6.2.2.4. Inhalation
15.6.2.2.5. Others
15.6.2.3. UAE
Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By End-Users
15.6.2.3.1. Hospitals
and Clinics
15.6.2.3.2. Pharmacies
15.6.2.3.3. Urgent
Care Centers
15.6.2.3.4. Research
Institutes
15.6.2.3.5. Others
15.6.2.4. UAE
Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Disorder Type
15.6.2.4.1. Major
and Minor Depression
15.6.2.4.2. Obsessive
Compulsive Disorder
15.6.2.4.3. Generalized
Anxiety
15.6.2.4.4. Posttraumatic
Stress (PTSD)
15.6.2.4.5. Social
Anxiety
15.6.2.4.6. Agitation
and Stress
15.6.2.4.7. Bipolar
Disorder
15.6.2.4.8. Others
15.6.3. Egypt
15.6.3.1. Egypt
Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Type
15.6.3.1.1. Serotonin
and Noradrenaline Reuptake Inhibitors (SNRIs)
15.6.3.1.2. Selective
Serotonin Reuptake Inhibitors (SSRIs)
15.6.3.1.3. Tricyclic
Antidepressants (TCAs)
15.6.3.1.4. Monoamine
Oxidase Inhibitors (MAOIs)
15.6.3.1.5. Noradrenaline
and Specific Serotoninergic Antidepressants (NaSSAs)
15.6.3.2. Egypt
Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Mode of
Administration
15.6.3.2.1. Tablets
and Capsules
15.6.3.2.2. Liquids
15.6.3.2.3. Injections
15.6.3.2.4. Inhalation
15.6.3.2.5. Others
15.6.3.3. Egypt
Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By End-Users
15.6.3.3.1. Hospitals
and Clinics
15.6.3.3.2. Pharmacies
15.6.3.3.3. Urgent
Care Centers
15.6.3.3.4. Research
Institutes
15.6.3.3.5. Others
15.6.3.4. Egypt
Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Disorder Type
15.6.3.4.1. Major
and Minor Depression
15.6.3.4.2. Obsessive
Compulsive Disorder
15.6.3.4.3. Generalized
Anxiety
15.6.3.4.4. Posttraumatic
Stress (PTSD)
15.6.3.4.5. Social
Anxiety
15.6.3.4.6. Agitation
and Stress
15.6.3.4.7. Bipolar
Disorder
15.6.3.4.8. Others
15.6.4. Kuwait
15.6.4.1. Kuwait
Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Type
15.6.4.1.1. Serotonin
and Noradrenaline Reuptake Inhibitors (SNRIs)
15.6.4.1.2. Selective
Serotonin Reuptake Inhibitors (SSRIs)
15.6.4.1.3. Tricyclic
Antidepressants (TCAs)
15.6.4.1.4. Monoamine
Oxidase Inhibitors (MAOIs)
15.6.4.1.5. Noradrenaline
and Specific Serotoninergic Antidepressants (NaSSAs)
15.6.4.2. Kuwait
Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Mode of
Administration
15.6.4.2.1. Tablets
and Capsules
15.6.4.2.2. Liquids
15.6.4.2.3. Injections
15.6.4.2.4. Inhalation
15.6.4.2.5. Others
15.6.4.3. Kuwait
Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By End-Users
15.6.4.3.1. Hospitals
and Clinics
15.6.4.3.2. Pharmacies
15.6.4.3.3. Urgent
Care Centers
15.6.4.3.4. Research
Institutes
15.6.4.3.5. Others
15.6.4.4. Kuwait
Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Disorder Type
15.6.4.4.1. Major
and Minor Depression
15.6.4.4.2. Obsessive
Compulsive Disorder
15.6.4.4.3. Generalized
Anxiety
15.6.4.4.4. Posttraumatic
Stress (PTSD)
15.6.4.4.5. Social
Anxiety
15.6.4.4.6. Agitation
and Stress
15.6.4.4.7. Bipolar
Disorder
15.6.4.4.8. Others
15.6.5. South
Africa
15.6.5.1. South
Africa Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Type
15.6.5.1.1. Serotonin
and Noradrenaline Reuptake Inhibitors (SNRIs)
15.6.5.1.2. Selective
Serotonin Reuptake Inhibitors (SSRIs)
15.6.5.1.3. Tricyclic
Antidepressants (TCAs)
15.6.5.1.4. Monoamine
Oxidase Inhibitors (MAOIs)
15.6.5.1.5. Noradrenaline
and Specific Serotoninergic Antidepressants (NaSSAs)
15.6.5.2. South
Africa Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Mode of
Administration
15.6.5.2.1. Tablets
and Capsules
15.6.5.2.2. Liquids
15.6.5.2.3. Injections
15.6.5.2.4. Inhalation
15.6.5.2.5. Others
15.6.5.3. South
Africa Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By End-Users
15.6.5.3.1. Hospitals
and Clinics
15.6.5.3.2. Pharmacies
15.6.5.3.3. Urgent
Care Centers
15.6.5.3.4. Research
Institutes
15.6.5.3.5. Others
15.6.5.4. South
Africa Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Disorder
Type
15.6.5.4.1. Major
and Minor Depression
15.6.5.4.2. Obsessive
Compulsive Disorder
15.6.5.4.3. Generalized
Anxiety
15.6.5.4.4. Posttraumatic
Stress (PTSD)
15.6.5.4.5. Social
Anxiety
15.6.5.4.6. Agitation
and Stress
15.6.5.4.7. Bipolar
Disorder
15.6.5.4.8. Others
15.6.6. Rest of
Middle East & Africa
15.6.6.1. Rest
of Middle East & Africa Antidepressant Drugs Market Revenue (US$ Mn) and
Forecasts, By Type
15.6.6.1.1. Serotonin
and Noradrenaline Reuptake Inhibitors (SNRIs)
15.6.6.1.2. Selective
Serotonin Reuptake Inhibitors (SSRIs)
15.6.6.1.3. Tricyclic
Antidepressants (TCAs)
15.6.6.1.4. Monoamine
Oxidase Inhibitors (MAOIs)
15.6.6.1.5. Noradrenaline
and Specific Serotoninergic Antidepressants (NaSSAs)
15.6.6.2. Rest
of Middle East & Africa Antidepressant Drugs Market Revenue (US$ Mn) and
Forecasts, By Mode of Administration
15.6.6.2.1. Tablets
and Capsules
15.6.6.2.2. Liquids
15.6.6.2.3. Injections
15.6.6.2.4. Inhalation
15.6.6.2.5. Others
15.6.6.3. Rest
of Middle East & Africa Antidepressant Drugs Market Revenue (US$ Mn) and
Forecasts, By End-Users
15.6.6.3.1. Hospitals
and Clinics
15.6.6.3.2. Pharmacies
15.6.6.3.3. Urgent
Care Centers
15.6.6.3.4. Research
Institutes
15.6.6.3.5. Others
15.6.6.4. Rest
of Middle East & Africa Antidepressant Drugs Market Revenue (US$ Mn) and
Forecasts, By Disorder Type
15.6.6.4.1. Major
and Minor Depression
15.6.6.4.2. Obsessive
Compulsive Disorder
15.6.6.4.3. Generalized
Anxiety
15.6.6.4.4. Posttraumatic
Stress (PTSD)
15.6.6.4.5. Social
Anxiety
15.6.6.4.6. Agitation
and Stress
15.6.6.4.7. Bipolar
Disorder
15.6.6.4.8. Others
15.7. Key
Segment for Channeling Investments
15.7.1. By
Country
15.7.2. By Type
15.7.3. By Mode
of Administration
15.7.4. By
End-Users
15.7.5. By
Disorder Type
16. Latin
America Antidepressant Drugs Market Analysis and Forecasts, 2020 - 2028
16.1. Overview
16.1.1. Latin
America Antidepressant Drugs Market Revenue (US$ Mn)
16.2. Latin
America Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Type
16.2.1. Serotonin
and Noradrenaline Reuptake Inhibitors (SNRIs)
16.2.2. Selective
Serotonin Reuptake Inhibitors (SSRIs)
16.2.3. Tricyclic
Antidepressants (TCAs)
16.2.4. Monoamine
Oxidase Inhibitors (MAOIs)
16.2.5. Noradrenaline
and Specific Serotoninergic Antidepressants (NaSSAs)
16.3. Latin
America Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Mode of
Administration
16.3.1. Tablets
and Capsules
16.3.2. Liquids
16.3.3. Injections
16.3.4. Inhalation
16.3.5. Others
16.4. Latin
America Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By
End-Users
16.4.1. Hospitals
and Clinics
16.4.2. Pharmacies
16.4.3. Urgent
Care Centers
16.4.4. Research
Institutes
16.4.5. Others
16.5. Latin
America Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Disorder
Type
16.5.1. Major
and Minor Depression
16.5.2. Obsessive
Compulsive Disorder
16.5.3. Generalized
Anxiety
16.5.4. Posttraumatic
Stress (PTSD)
16.5.5. Social
Anxiety
16.5.6. Agitation
and Stress
16.5.7. Bipolar
Disorder
16.5.8. Others
16.6. Latin
America Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Country
16.6.1. Brazil
16.6.1.1. Brazil
Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Type
16.6.1.1.1. Serotonin
and Noradrenaline Reuptake Inhibitors (SNRIs)
16.6.1.1.2. Selective
Serotonin Reuptake Inhibitors (SSRIs)
16.6.1.1.3. Tricyclic
Antidepressants (TCAs)
16.6.1.1.4. Monoamine
Oxidase Inhibitors (MAOIs)
16.6.1.1.5. Noradrenaline
and Specific Serotoninergic Antidepressants (NaSSAs)
16.6.1.2. Brazil
Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Mode of
Administration
16.6.1.2.1. Tablets
and Capsules
16.6.1.2.2. Liquids
16.6.1.2.3. Injections
16.6.1.2.4. Inhalation
16.6.1.2.5. Others
16.6.1.3. Brazil
Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By End-Users
16.6.1.3.1. Hospitals
and Clinics
16.6.1.3.2. Pharmacies
16.6.1.3.3. Urgent
Care Centers
16.6.1.3.4. Research
Institutes
16.6.1.3.5. Others
16.6.1.4. Brazil
Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Disorder Type
16.6.1.4.1. Major
and Minor Depression
16.6.1.4.2. Obsessive
Compulsive Disorder
16.6.1.4.3. Generalized
Anxiety
16.6.1.4.4. Posttraumatic
Stress (PTSD)
16.6.1.4.5. Social
Anxiety
16.6.1.4.6. Agitation
and Stress
16.6.1.4.7. Bipolar
Disorder
16.6.1.4.8. Others
16.6.2. Argentina
16.6.2.1. Argentina
Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Type
16.6.2.1.1. Serotonin
and Noradrenaline Reuptake Inhibitors (SNRIs)
16.6.2.1.2. Selective
Serotonin Reuptake Inhibitors (SSRIs)
16.6.2.1.3. Tricyclic
Antidepressants (TCAs)
16.6.2.1.4. Monoamine
Oxidase Inhibitors (MAOIs)
16.6.2.1.5. Noradrenaline
and Specific Serotoninergic Antidepressants (NaSSAs)
16.6.2.2. Argentina
Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Mode of
Administration
16.6.2.2.1. Tablets
and Capsules
16.6.2.2.2. Liquids
16.6.2.2.3. Injections
16.6.2.2.4. Inhalation
16.6.2.2.5. Others
16.6.2.3. Argentina
Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By End-Users
16.6.2.3.1. Hospitals
and Clinics
16.6.2.3.2. Pharmacies
16.6.2.3.3. Urgent
Care Centers
16.6.2.3.4. Research
Institutes
16.6.2.3.5. Others
16.6.2.4. Argentina
Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Disorder Type
16.6.2.4.1. Major
and Minor Depression
16.6.2.4.2. Obsessive
Compulsive Disorder
16.6.2.4.3. Generalized
Anxiety
16.6.2.4.4. Posttraumatic
Stress (PTSD)
16.6.2.4.5. Social
Anxiety
16.6.2.4.6. Agitation
and Stress
16.6.2.4.7. Bipolar
Disorder
16.6.2.4.8. Others
16.6.3. Rest of
Latin America
16.6.3.1. Rest
of Latin America Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By
Type
16.6.3.1.1. Serotonin
and Noradrenaline Reuptake Inhibitors (SNRIs)
16.6.3.1.2. Selective
Serotonin Reuptake Inhibitors (SSRIs)
16.6.3.1.3. Tricyclic
Antidepressants (TCAs)
16.6.3.1.4. Monoamine
Oxidase Inhibitors (MAOIs)
16.6.3.1.5. Noradrenaline
and Specific Serotoninergic Antidepressants (NaSSAs)
16.6.3.2. Rest
of Latin America Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By
Mode of Administration
16.6.3.2.1. Tablets
and Capsules
16.6.3.2.2. Liquids
16.6.3.2.3. Injections
16.6.3.2.4. Inhalation
16.6.3.2.5. Others
16.6.3.3. Rest
of Latin America Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By
End-Users
16.6.3.3.1. Hospitals
and Clinics
16.6.3.3.2. Pharmacies
16.6.3.3.3. Urgent
Care Centers
16.6.3.3.4. Research
Institutes
16.6.3.3.5. Others
16.6.3.4. Rest
of Latin America Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By
Disorder Type
16.6.3.4.1. Major
and Minor Depression
16.6.3.4.2. Obsessive
Compulsive Disorder
16.6.3.4.3. Generalized
Anxiety
16.6.3.4.4. Posttraumatic
Stress (PTSD)
16.6.3.4.5. Social
Anxiety
16.6.3.4.6. Agitation
and Stress
16.6.3.4.7. Bipolar
Disorder
16.6.3.4.8. Others
16.7. Key
Segment for Channeling Investments
16.7.1. By
Country
16.7.2. By Type
16.7.3. By Mode
of Administration
16.7.4. By
End-Users
16.7.5. By
Disorder Type
17. Competitive
Benchmarking
17.1. Market
Share Analysis, 2019
17.2. Global
Presence and Growth Strategies
17.2.1. Mergers
and Acquisitions
17.2.2. Product
Launches
17.2.3. Investments
Trends
17.2.4. R&D
Initiatives
18. Player
Profiles
18.1. Abbot
18.1.1. Company
Details
18.1.2. Company
Overview
18.1.3. Product
Offerings
18.1.4. Key
Developments
18.1.5. Financial
Analysis
18.1.6. SWOT
Analysis
18.1.7. Business
Strategies
18.2. AbbVie
18.2.1. Company
Details
18.2.2. Company
Overview
18.2.3. Product
Offerings
18.2.4. Key
Developments
18.2.5. Financial
Analysis
18.2.6. SWOT
Analysis
18.2.7. Business
Strategies
18.3. AstraZeneca
18.3.1. Company
Details
18.3.2. Company
Overview
18.3.3. Product
Offerings
18.3.4. Key
Developments
18.3.5. Financial
Analysis
18.3.6. SWOT
Analysis
18.3.7. Business
Strategies
18.4. Eli Lilly
and Company
18.4.1. Company
Details
18.4.2. Company
Overview
18.4.3. Product
Offerings
18.4.4. Key
Developments
18.4.5. Financial
Analysis
18.4.6. SWOT
Analysis
18.4.7. Business
Strategies
18.5. F.
Hoffmann-La Roche Ltd
18.5.1. Company
Details
18.5.2. Company
Overview
18.5.3. Product
Offerings
18.5.4. Key
Developments
18.5.5. Financial
Analysis
18.5.6. SWOT
Analysis
18.5.7. Business
Strategies
18.6. GlaxoSmithKline
plc.
18.6.1. Company
Details
18.6.2. Company
Overview
18.6.3. Product
Offerings
18.6.4. Key
Developments
18.6.5. Financial
Analysis
18.6.6. SWOT
Analysis
18.6.7. Business
Strategies
18.7. H.
Lundbeck A/S
18.7.1. Company
Details
18.7.2. Company
Overview
18.7.3. Product
Offerings
18.7.4. Key
Developments
18.7.5. Financial
Analysis
18.7.6. SWOT
Analysis
18.7.7. Business
Strategies
18.8. Janssen
Pharmaceuticals, Inc
18.8.1. Company
Details
18.8.2. Company
Overview
18.8.3. Product
Offerings
18.8.4. Key
Developments
18.8.5. Financial
Analysis
18.8.6. SWOT
Analysis
18.8.7. Business
Strategies
18.9. Lupin
Pharmaceuticals, Inc
18.9.1. Company
Details
18.9.2. Company
Overview
18.9.3. Product
Offerings
18.9.4. Key
Developments
18.9.5. Financial
Analysis
18.9.6. SWOT
Analysis
18.9.7. Business
Strategies
18.10. Merck
& Co., Inc.
18.10.1. Company
Details
18.10.2. Company
Overview
18.10.3. Product
Offerings
18.10.4. Key
Developments
18.10.5. Financial
Analysis
18.10.6. SWOT
Analysis
18.10.7. Business
Strategies
18.11. Novartis
AG
18.11.1. Company
Details
18.11.2. Company
Overview
18.11.3. Product
Offerings
18.11.4. Key
Developments
18.11.5. Financial
Analysis
18.11.6. SWOT
Analysis
18.11.7. Business
Strategies
18.12. Pfizer
Inc.
18.12.1. Company
Details
18.12.2. Company
Overview
18.12.3. Product
Offerings
18.12.4. Key
Developments
18.12.5. Financial
Analysis
18.12.6. SWOT
Analysis
18.12.7. Business
Strategies
18.13. sanofi-aventis
U.S. LLC
18.13.1. Company
Details
18.13.2. Company
Overview
18.13.3. Product
Offerings
18.13.4. Key
Developments
18.13.5. Financial
Analysis
18.13.6. SWOT
Analysis
18.13.7. Business
Strategies
18.14. Sun
Pharmaceutical Industries Ltd.
18.14.1. Company
Details
18.14.2. Company
Overview
18.14.3. Product
Offerings
18.14.4. Key
Developments
18.14.5. Financial
Analysis
18.14.6. SWOT Analysis
18.14.7. Business
Strategies
18.15. Takeda
Pharmaceutical Company Limited
18.15.1. Company
Details
18.15.2. Company
Overview
18.15.3. Product
Offerings
18.15.4. Key
Developments
18.15.5. Financial
Analysis
18.15.6. SWOT
Analysis
18.15.7. Business
Strategies
18.16. Teva
Pharmaceutical Industries Ltd
18.16.1. Company
Details
18.16.2. Company
Overview
18.16.3. Product
Offerings
18.16.4. Key
Developments
18.16.5. Financial
Analysis
18.16.6. SWOT
Analysis
18.16.7. Business Strategies
18.17. Other
Industry Participants
19. Key
Findings
Note: This ToC is tentative
and can be changed according to the research study conducted during the course
of report completion.
**Exclusive for Multi-User and
Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
Reach to us
Call us on
+91-74002-42424
Drop us an email at
sales@absolutemarketsinsights.com
Why Absolute Markets Insights?
An effective strategy is the entity that influences a business to stand out of the crowd. An organization with a phenomenal strategy for success dependably has the edge over the rivals in the market. It offers the organizations a head start in planning their strategy. Absolute Market Insights is the new initiation in the industry that will furnish you with the lead your business needs. Absolute Market Insights is the best destination for your business intelligence and analytical solutions; essentially because our qualitative and quantitative sources of information are competent to give one-stop solutions. We inventively combine qualitative and quantitative research in accurate proportions to have the best report, which not only gives the most recent insights but also assists you to grow.